27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
- Needham initiated coverage on Fate Therapeutics Inc (NASDAQ:FATE) with a Hold rating without a price target.
- The company is working on induced pluripotent stem cell (iPSC) derived cancer therapeutics, primarily NK cells.
- Needham says that Fate's platform has several appealing qualities:
- NK cells are natively allogeneic.
- Using iPSCs allows for improved scalability and controlled COGS while achieving efficacies in line with the most advanced therapeutics.
- Early proof of concept was achieved in B-cell leukemias & lymphomas (BCL) and acute myeloid leukemia.
- Related: Despite Durability Questions, BMO Upgraded This Natural-Killer Cell Therapy Oncology Stock.
- However, questions regarding treatment durability remain.
- In BCL, durability is trending towards a ~27% CR rate at six months, which is on the low end compared to commercial CAR-Ts (29-36%).
- Longer-term follow-up from allogeneic programs can provide a better understanding of treatment durability.
- "We consider Fate's platform a compelling solution in solid tumors, despite NK iPSCs having low activity at baseline. At current levels, we consider FATE fully valued based on its potential in hematological malignancies," said Needham.
- Price Action: FATE shares are down 2.77% at $32.25 during the market session on the last check Thursday.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!